Hints and tips:
Showing results for Rudisill v. Takeda Pharmaceuticals America Inc
Related Special Reports
...Idexx said in October that the animal health market had experienced a “V-shaped recovery”....
...Their concentrated ownership of industries such as airlines and pharmaceuticals may push up travel and drug prices, some academics argue....
...The latest acquisition contributes to a record year for Japanese outbound deals, led by Takeda Pharmaceutical’s £46bn agreement to buy Irish drugmaker Shire in April....
...Others focused on the significance of Takeda’s move for its country’s pharmaceuticals industry....
...The combined value of those deals — which include Takeda Pharmaceutical’s ¥7tn planned takeover of Shire — was around ¥11.7tn....
...Separately, Japan’s Takeda Pharmaceutical has reached a preliminary agreement to buy Irish drugmaker Shire for about £46bn, a deal that could spark a renewed wave of “big pharma” deals....
...Corporate giants including US cable group Comcast, wireless provider T-Mobile and Japan’s pharmaceutical maker Takeda reached for M&A to head off competitive threats and expand their businesses....
...Pharmaceutical groups, which might see similar benefits from quantum technology in the long term, are still on the sidelines....
...In the latest sign of how eager boardrooms are sparking a record number of “megadeals”, Japan’s top drugmaker Takeda revealed it was weighing a $40bn takeover of Irish rival Shire....
...Separately, Hikma disclosed on Thursday that it will expand its licensing and distribution pact with Japan’s Takeda Pharmaceuticals that will add new products to its Middle East and North Africa portfolio...
...Thanks to a series of court rulings since the mid-2000s, such as eBay v MercExchange in 2007, Mayo Collaborative Services v Prometheus Laboratories in 2012 and Alice Corp v CLS Bank in 2014, and the subsequent...
...Thomas Sheehan, head of global healthcare at Bank of America Merrill Lynch, said despite the slowdown the fundamentals for dealmaking remained unchanged and activity was bound to pick up again....
...Cancer drug maker Takeda Pharmaceutical, fell 2.6 per cent following Trump’s comments....
..., the pharmaceutical company....
...In Japan, Takeda Pharmaceutical slid 2.7 per cent, Astellas Pharma fell 3.9 per cent and Shionogi sank 3.7 per cent on Thursday morning, while in Australia biotech company CSL Ltd dropped 1.4 per cent and...
...For GlaxoSmithKline and AstraZeneca — twin pillars of Britain’s pharmaceuticals sector — 2016 promises to be a critical year....
...The investment came a day after AstraZeneca agreed to pay Takeda of Japan $575m for a portfolio of respiratory medicines and a month after it bought ZS Pharma, a US biotech company, for $2.7bn....
...Cash-rich Japanese drugmakers have been on a spending spree ahead of the so-called “patent cliff”, highlighted by Takeda Pharmaceutical’s $13.7bn purchase of Nycomed, the Swiss drugmaker, in 2011....
...Domestic sales at Japan’s five biggest pharmaceuticals groups – Takeda, Astellas Pharma, Daiichi Sankyo, Eisai and Chugai Pharmaceutical – account for between 45 and 90 per cent of revenues....
...But pharmaceutical leaders need to take a hard look at themselves....
...(Financial Times) Roche is to buy Santaris Pharma for up to $450m in the latest piece of dealmaking by the Swiss pharmaceuticals group....
...Nycomed, now part of Takeda of Japan, owns the rights to the medicine and licensed it exclusively in the US to Wyeth, which is now part of Pfizer....
...Two year’s later Aspen paid R6.1bn for the pharmaceutical business of Australian-based Sigma Pharmaceuticals to bolster its expansion plans in the Asia Pacific region....
...Japanese companies have proved more active: Eisai partnered with Arena and Takeda with Orexigen....
...Bausch & Lomb makes contact lenses, lens care solutions as well as ophthalmic surgical and pharmaceutical products....
International Edition